0.48
Xtant Medical Holdings Inc stock is traded at $0.48, with a volume of 128.73K.
It is up +2.11% in the last 24 hours and down -6.98% over the past month.
Xtant Medical Holdings, Inc. develops, manufactures, and markets regenerative medicine products and devices for orthopedic and neurological surgeons in the United States and internationally. Its biomaterial products include OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSponge SC that fills bony defects in the subchondral region of joints; OsteoSelect DBM Putty for osteoinductive bone growth; OsteoSelect PLUS for use as a bone void filler and bone graft substitute in the pelvis, extremities, and posterolateral spine; and OsteoWrap that wraps around non-union fractures to assist with fusion, as well as could be used in conjunction with a hardware plate system. The company also provides OsteoSTX for posterolateral spine surgery applications, including scoliosis procedures; and 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone. In addition, it processes and distributes sports allografts for anterior and posterior cruciate ligament repairs, anterior cruciate ligament reconstruction, and meniscal repair; milled spinal allografts for cortical bone milled to desired shapes and dimensions; and traditional allografts for orthopedics, neurology, podiatry, oral/maxillofacial, genitourinary, and plastic/reconstructive applications. Further, the company offers various products to treat a range of spinal and sacroiliac conditions, including trauma, degeneration, deformity, and tumor. Xtant Medical Holdings, Inc. markets its products through direct sales, consignment agents, reseller distributors, private label distributors, and technology licensees. The company was formerly known as Bacterin International Holdings, Inc. and changed its name to Xtant Medical Holdings, Inc. in July 2015. Xtant Medical Holdings, Inc. is headquartered in Belgrade, Montana.
See More
Previous Close:
$0.4701
Open:
$0.466
24h Volume:
128.73K
Relative Volume:
0.86
Market Cap:
$67.33M
Revenue:
$121.91M
Net Income/Loss:
$1.83M
P/E Ratio:
44.04
EPS:
0.0109
Net Cash Flow:
$7.75M
1W Performance:
+5.29%
1M Performance:
-6.98%
6M Performance:
-22.71%
1Y Performance:
-33.93%
Xtant Medical Holdings Inc Stock (XTNT) Company Profile
Name
Xtant Medical Holdings Inc
Sector
Industry
Phone
406-388-0480
Address
664 Cruiser Lane, Belgrade, MT
Compare XTNT vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
XTNT
Xtant Medical Holdings Inc
|
0.48 | 65.94M | 121.91M | 1.83M | 7.75M | 0.0109 |
|
ABT
Abbott Laboratories
|
87.41 | 152.88B | 45.13B | 6.28B | 7.38B | 3.5895 |
|
SYK
Stryker Corp
|
316.48 | 120.18B | 25.27B | 3.34B | 4.57B | 8.6334 |
|
MDT
Medtronic Plc
|
78.60 | 100.34B | 35.48B | 4.64B | 5.41B | 3.582 |
|
BSX
Boston Scientific Corp
|
57.78 | 84.95B | 20.62B | 3.56B | 3.48B | 2.3847 |
|
EW
Edwards Lifesciences Corp
|
85.78 | 47.91B | 6.30B | 1.07B | 1.09B | 1.8406 |
Xtant Medical Holdings Inc Stock (XTNT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-05-23 | Initiated | BTIG Research | Buy |
| Nov-15-18 | Reiterated | Maxim Group | Buy |
| Feb-14-18 | Reiterated | Maxim Group | Buy |
Xtant Medical Holdings Inc Stock (XTNT) Latest News
XTNT Q1 2026 Earnings: EPS Misses Estimates Despite Stock GainCommunity Hot Stocks - Newser
Xtant Medical Holdings Inc. (XTNT) Q1 2026 Earnings: EPS Misses Estimates Amidst Narrow LossSenior Analyst Forecasts - Newser
Xtant Medical Holdings (XTNT) Edges Higher: Testing Key Resistance at $0.50Shared Buy Zones - Newser
Xtant Medical Holdings Holds Near Key Resistance Level After Modest GainCommunity Chart Signals - Newser
Xtant Medical Holdings (XTNT) Gains 2.08% as Stock Approaches Key Resistance at $0.50Profitability Factor - Newser
Xtant Medical Balances New Growth Bets With Near-Term Pain - TipRanks
Xtant Medical launches pre-shaped bone graft product line By Investing.com - Investing.com Nigeria
XTNT SEC FilingsXtant Medical 10-K, 10-Q, 8-K Forms - Stock Titan
Xtant Medical raises FY 2026 revenue guidance to $101M-$105M as it adds HEMOBLAST distribution rights - MSN
Xtant Medical Q1 Earnings Call Highlights - Yahoo Finance
B. Riley Financial | Diversified Financial Services Platform - FinancialContent
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Xtant Medical Holdings’ revenue drops to USD 20.9M in Q1 2026 - Medical Buyer
Xtant Medical Holdings, Inc. (AMEX:XTNT) Q1 2026 Earnings Call Transcript - Insider Monkey
Xtant Medical Holdings, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Xtant Medical Boosts 2026 Outlook Amid Tough Quarter - TipRanks
Xtant Medical Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Xtant Medical Holdings Inc Q1 2026 Earnings: Revenue Misses $20.9 million - technotrenz.com
Xtant Medical Holdings, Inc. 2026 Q1 10-Q Report: Financial Results, Strategic Initiatives, and Key Risk Factors - Minichart
Xtant Medical Q1 2026 Results: Revenue Guidance Raised, Balance Sheet Strengthened, Exclusive HEMOBLAST® Bellows Distribution Secured 12 - Minichart
Xtant Medical Q1 2026 Earnings Call Transcript - MarketBeat
XTNT: Raised 2026 revenue guidance to $101M–$105M amid new product launches and reduced debt - TradingView
Xtant Medical Reports First Quarter 2026 Results and Raises Guidance - HarianBasis.co
Xtant Medical Hldgs Q1 2026 Earnings Call Transcript - Yahoo Finance
Xtant Medical launches Trivium Shaped allograft for surgeries - MSN
Xtant Medical Updates Q1 Results and Raises 2026 Guidance - TipRanks
XTNT: Q1 2026 revenue dropped 37% and net loss reached $3.1M amid asset sales and reimbursement shifts - TradingView
Xtant Medical (XTNT) Q1 2026 revenue drops 37% as divestitures hit sales - Stock Titan
XTNT: Raised 2026 revenue guidance to $101–$105M amid asset sales, new product launches, and debt reduction - TradingView
Xtant Medical (NYSE: XTNT) cuts debt, raises 2026 revenue guidance after Q1 - Stock Titan
Press Release: Xtant Medical Reports First Quarter 2026 Financial Results - Moomoo
MSN Money - MSN
TradingKey - tradingkey.com
Xtant Medical Expands Trivium™ Portfolio with the Commercial Launch of Trivium™ Shaped - Orthopedics This Week
May 13 before trading: Xtant Medical posts Q1 results, 8:30 ET call - Stock Titan
Xtant Medical to Announce First Quarter 2026 Financial Results on May 13, 2026 - Morningstar
Xtant Medical launches pre-shaped bone graft product line - Investing.com UK
Xtant rolls out ready-to-use bone graft forms for spine surgery - Stock Titan
Xtant Medical Holdings (XTNT) price target increased by 12.12% to 1.26 - MSN
Xtant Medical Holdings Inc Stock (XTNT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):